Immorta Bio’s nine-amino-acid peptide aims at zombie cells
Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end. The molecule at the center of Immorta Bio’s latest announcement is just nine amino acids long, which is tiny by drug standards. On 12 October, the Miami company
<p>Immorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end. The molecule at the center of Immorta Bio’s latest announcement is just nine amino acids long, which is tiny by drug standards. On 12 October, the Miami company </p>